Bausch + Lomb Appoints Two New Directors to Accelerate Strategy

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Dec 17 2025

0mins

BLCO+3.6%

Should l Buy BLCO?

Source: Newsfilter

New Board Members: Bausch + Lomb announced the appointment of Dr. Eduardo C. Alfonso and Steven H. Collis to its board effective January 1, 2026, expanding the board to 10 members, aimed at enhancing strategic execution through diversified leadership.
Industry Expert Addition: Dr. Alfonso is a globally recognized ophthalmologist with a strong background in corneal diseases from Bascom Palmer Eye Institute, whose expertise will provide critical guidance for the company's innovations in eye health.
Financial Growth Driver: Collis led Cencora to triple its annual revenue and significantly expanded its global presence through strategic acquisitions, and his extensive financial management experience will support Bausch + Lomb's sustainable growth.
Future Strategic Direction: The addition of these two directors not only enhances the board's expertise but also propels Bausch + Lomb's innovation and development in the eye health market, helping the company seize significant future opportunities.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BLCO?" and start using high-conviction signals backed by rigorous historical data.

BLCO

$17+Infinity%1D

Analyst Views on BLCO

Wall Street analysts forecast BLCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 17.36 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Analyst Rating

4 Buy

7 Hold

1 Sell

Hold

Current: 16.410

Low

13.00

Averages

17.36

High

21.00

Current: 16.410

Low

13.00

Averages

17.36

High

21.00

RBC Capital

Outperform

maintain

$19 -> $21

2026-01-27

Reason

RBC Capital

Price Target

$19 -> $21

AI Analysis

2026-01-27

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Bausch + Lomb to $21 from $19 and keeps an Outperform rating on the shares ahead of its Q4 results. The firm is positive on FX tailwinds and also expects 2026 guidance and Rx DED - dry-eye disease - portfolio to be key areas of focus, the analyst tells investors in a research note.

Goldman Sachs

David Roman

Neutral

maintain

$17 -> $19

2026-01-09

Reason

Goldman Sachs

David Roman

Price Target

$17 -> $19

2026-01-09

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on Bausch + Lomb to $19 from $17 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BLCO

Unlock Now

About BLCO

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bausch + Lomb Launches Fifth Annual Glaucoma Fundraising Challenge with $20,000 Match

Jan 05 2026Newsfilter

Fundraising Challenge: Bausch + Lomb is launching its fifth annual fundraising challenge in partnership with the Glaucoma Research Foundation during Glaucoma Awareness Month, pledging to match every dollar raised up to $20,000 in January to support critical glaucoma research aimed at enhancing public awareness of this leading cause of blindness.
Social Media Campaign: The company will also sponsor The Glaucoma Foundation's social media campaign, which highlights a glaucoma patient or advocate's story each day in January, thereby raising awareness of the disease's impact and emphasizing the importance of early detection to help more individuals focus on eye health.
Disease Impact: Currently, approximately four million people in the United States are affected by glaucoma, and this number is expected to grow as the population ages, making enhanced education and research vital for improving the quality of life for those affected.
Strategic Collaboration: The partnership between Bausch + Lomb, the Glaucoma Research Foundation, and The Glaucoma Foundation not only advances glaucoma research but also encourages public awareness and proactive eye health measures, reflecting the company's commitment and responsibility in the eye health sector.

Bausch + Lomb Completes $2.8 Billion Credit Agreement Refinancing

Jan 02 2026Businesswire

Credit Agreement Refinancing: Bausch + Lomb has completed a $2.8 billion credit agreement refinancing, utilizing the Fourth Amendment to refinance maturing loans, thereby alleviating future financial pressure.
Loan Terms Optimization: The new loans feature an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026, which is expected to improve the company's cash flow management compared to previous terms.
Interest Rate Reduction: The applicable margin for the replacement loans is reduced by 0.50% and 0.25% from prior loans, which will help lower financing costs and enhance financial flexibility for the company.
Maturity Extension: The new loans will mature on January 15, 2031, extending the maturity of existing loans and allowing the company to better plan its financial strategy over the coming years.

Bausch + Lomb to Present at 2026 J.P. Morgan Healthcare Conference

Dec 23 2025Businesswire

Executive Participation: Bausch + Lomb's Chairman and CEO Brent Saunders will speak at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing the company's latest advancements in eye health, which is expected to attract investor interest.
Financial Leadership Involvement: CFO Sam Eldessouky will also participate in the conference, providing updates on the company's financial status, aimed at bolstering investor confidence in the company's future growth.
R&D Leadership Presentation: Chief Medical Officer and Head of R&D Yehia Hashad, MD, will discuss the company's innovative products, emphasizing Bausch + Lomb's commitment to research and development in eye health, potentially enhancing market recognition of its offerings.
Live Webcast: The event will be available via live webcast on Bausch + Lomb's Investor Relations page, ensuring that investors unable to attend in person can access key information, further enhancing the company's transparency and investor relations.